{"nctId":"NCT02593097","briefTitle":"Metformin for the Prevention of Episodic Migraine (MPEM)","startDateStruct":{"date":"2016-02"},"conditions":["Migraine"],"count":34,"armGroups":[{"label":"Metformin first, then matching placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Matching Placebo"]},{"label":"Matching placebo first, then Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Matching Placebo"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Matching Placebo","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. age 18-65 years\n2. a diagnosis of migraine with or without aura for \\>1 year according to the International Classification of Headache Disorders-IIIb\n\nExclusion Criteria:\n\n1. a diagnosis of diabetes mellitus or polycystic ovarian syndrome\n2. overuse of acute migraine treatments\n3. failure to respond to 3 or more classes of preventive drug treatments\n4. change in dose of migraine-preventive medication within 2 months of beginning the baseline diary phase\n5. significant somatic or psychiatric disease\n6. known alcohol or other substance abuse\n7. pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Headache Days","description":"Total number of moderate and severe headache days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.64","spread":"2.15"},{"groupId":"OG001","value":"24.33","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Greater Than >50% Reduction in Migraine Days on Metformin","description":"Percentage of patients whose migraines reduced by at least 50% on Metformin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Total number of subjects with treatment-related adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Dry Mouth","Diarrhea","Dry hair","Hair loss"]}}}